BL
NVO

Balentine LLC’s Novo Nordisk NVO Stock Holding History

Balentine LLC’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$410K Sell
11,163
-393
-3% -$18.6K 0.02% 133
2025
Q4 		$588K Sell
11,556
-210
-2% -$10.7K 0.02% 118
2025
Q3 		$653K Sell
11,766
-187
-2% -$10.9K 0.02% 104
2025
Q2 		$825K Sell
11,953
-213
-2% -$14.5K 0.03% 76
2025
Q1 		$845K Hold
12,166
– – 0.04% 78
2024
Q4 		$1.05M Sell
12,166
-315
-3% -$34.1K 0.04% 53
2024
Q3 		$1.49M Buy
12,481
+2
+0% +$267 0.06% 52
2024
Q2 		$1.78M Sell
12,479
-70,700
-85% -$9.37M 0.08% 39
2024
Q1 		$10.7M Buy
83,179
+1,875
+2% +$223K 0.32% 28
2023
Q4 		$8.41M Buy
81,304
+12,741
+19% +$1.26M 0.27% 35
2023
Q3 		$6.24M Buy
68,563
+661
+1% +$58.2K 0.21% 42
2023
Q2 		$5.49M Buy
67,902
+2,004
+3% +$164K 0.18% 47
2023
Q1 		$5.24M Buy
65,898
+1,094
+2% +$77.6K 0.18% 45
2022
Q4 		$4.39M Buy
64,804
+11,588
+22% +$679K 0.15% 47
2022
Q3 		$2.65M Sell
53,216
-18,742
-26% -$1M 0.1% 61
2022
Q2 		$4.01M Buy
71,958
+20,152
+39% +$1.12M 0.15% 53
2022
Q1 		$2.88M Buy
51,806
+17,786
+52% +$913K 0.1% 55
2021
Q4 		$1.91M Buy
34,020
+7,160
+27% +$388K 0.07% 48
2021
Q3 		$1.29M Buy
26,860
+7,340
+38% +$355K 0.05% 51
2021
Q2 		$818K Buy
19,520
+2,250
+13% +$87.2K 0.03% 51
2021
Q1 		$582K Buy
17,270
+314
+2% +$11.2K 0.03% 59
2020
Q4 		$592K Buy
16,956
+246
+1% +$8.5K 0.03% 57
2020
Q3 		$580K Buy
16,710
+12,964
+346% +$432K 0.03% 53
2020
Q2 		$123K Buy
+3,746
New +$120K 0.01% 134
2019
Q4 		– Sell
-2,582
Closed -$67K – 700
2019
Q3 		$67K Hold
2,582
– – ﹤0.01% 116
2019
Q2 		$66K Buy
2,582
+260
+11% +$6.43K ﹤0.01% 90
2019
Q1 		$61K Hold
2,322
– – ﹤0.01% 110
2018
Q4 		$53K Buy
2,322
+392
+20% +$8.71K ﹤0.01% 109
2018
Q3 		$45K Buy
+1,930
New +$47.1K ﹤0.01% 75
2018
Q1 		– Sell
-1,436
Closed -$39K – 378
2017
Q4 		$39K Hold
1,436
– – ﹤0.01% 301
2017
Q3 		$35K Sell
1,436
-124
-8% -$2.8K ﹤0.01% 312
2017
Q2 		$33K Sell
1,560
-86
-5% -$1.74K ﹤0.01% 299
2017
Q1 		$28K Buy
1,646
+246
+18% +$4.28K ﹤0.01% 305
2016
Q4 		$25K Buy
1,400
+294
+27% +$5.33K ﹤0.01% 292
2016
Q3 		$23K Sell
1,106
-632
-36% -$15.7K ﹤0.01% 259
2016
Q2 		$47K Buy
1,738
+806
+86% +$22.1K 0.01% 154
2016
Q1 		$25K Hold
932
– – 0.01% 169
2015
Q4 		$27K Sell
932
-146
-14% -$4.04K 0.01% 219
2015
Q3 		$29K Hold
1,078
– – 0.01% 239
2015
Q2 		$30K Buy
1,078
+56
+5% +$1.57K ﹤0.01% 214
2015
Q1 		$27K Buy
+1,022
New +$23.5K 0.01% 210

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Balentine LLC's NVO Position: Q1 2026 in Review

Balentine LLC reduced its Novo Nordisk (NVO) stake by 3.4% in Q1 2026, selling an estimated $18.6K and leaving 11,163 shares worth $410K. The position accounts for 0.02% of the portfolio, ranked #133.

Balentine LLC first reported a position in NVO in Q1 2015 and has held it in 41 quarters since. The position peaked at $10.7M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Balentine LLC held 11,163 shares of Novo Nordisk worth $410K as of Q1 2026.
  • Balentine LLC sold 393 Novo Nordisk shares in Q1 2026, an estimated $18.6K.
  • Novo Nordisk made up 0.02% of Balentine LLC's portfolio in Q1 2026, its #133 holding.
  • Balentine LLC first reported a position in Novo Nordisk in Q1 2015 and has held it in 41 quarters since.
  • Balentine LLC's Novo Nordisk position peaked at $10.7M in Q1 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Balentine LLC's 13F filing for Q1 2026, filed 24 Apr 2026.